Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
Active, not recruiting · NCT04817241 · Registry updated 2026-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT04817241 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Montefiore Medical Center - Moses Campus | The Bronx | United States | 219 |
| Montefiore Medical Center-Einstein Campus | The Bronx | United States | 170 |
| Roswell Park Cancer Institute | Buffalo | United States | 382 |
| University of Alabama at Birmingham Cancer Center | Birmingham | United States | 186 |
| University of Virginia Cancer Center | Charlottesville | United States | 206 |
| Vanderbilt University/Ingram Cancer Center | Nashville | United States | 259 |
| Yale University | New Haven | United States | 352 |